Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Grace Therapeutics Inc GRCE

Healthcare Biotechnology
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a... see more

Recent & Breaking News (NDAQ:GRCE)

Acasti Pharma Recognizes Rare Disease Day

PR Newswire February 28, 2023

Acasti Pharma Reports Third Quarter 2023 Operational Results

GlobeNewswire February 14, 2023

Acasti Pharma to Report Third Quarter 2023 Financial Results on Tuesday, February 14, 2023

PR Newswire February 7, 2023

Acasti Receives Extension to Regain Compliance with NASDAQ Minimum Bid Price Rule

GlobeNewswire January 25, 2023

Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31

GlobeNewswire January 24, 2023

Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast

Newsfile January 17, 2023

Acasti Pharma to Present at Sidoti Virtual Investor Conference on January 18

GlobeNewswire January 13, 2023

Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures

GlobeNewswire January 5, 2023

Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company's Drug Candidate for the Treatment of Ataxia Telangiectasia

GlobeNewswire December 28, 2022

Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company's Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)

GlobeNewswire December 22, 2022

Acasti Pharma Reports Second Quarter 2023 Operational Results

GlobeNewswire November 14, 2022

Acasti Pharma to Present at Q4 Investor Summit

GlobeNewswire November 9, 2022

Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022

GlobeNewswire November 7, 2022

Acasti Announces Court Dismissal of Stockholder Litigation

GlobeNewswire September 30, 2022

Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders

GlobeNewswire September 29, 2022

Acasti Pharma Inc. Discusses Clinical Progress of Lead Assets and 2022 Catalysts with The Stock Day Podcast

Newsfile September 21, 2022

Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference

GlobeNewswire September 14, 2022

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company's Drug Candidate for the Treatment of Ataxia Telangiectasia

GlobeNewswire September 13, 2022

Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 12, 2022

Acasti Pharma Reports First Quarter 2023 Operational Results

GlobeNewswire August 11, 2022

Podcasts